The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1427
Brimonidine Gel (Mirvaso) for Rosacea
The full article is available to subscribers Subscriber Login   

The FDA has approved the selective alpha2-adrenergic receptor agonist brimonidine as a 0.33% gel (Mirvaso – Galderma) for topical treatment of adults with persistent facial erythema of rosacea. Brimonidine is also available in ophthalmic formulations for treatment of glaucoma.1,2

MECHANISM OF ACTION — Taken systemically, selective alpha2 agonists lower blood pressure by decreasing sympathetic outflow from the brain. Applied to the eye, they decrease production of aqueous humor. Applied to the skin, they cause vasoconstriction and can reduce erythema.

TREATMENT OF ROSACEA — Rosacea is a common, chronic inflammatory facial eruption of unknown cause characterized by erythema, telangiectasia, and recurrent, progressive crops of acneiform papules and pustules, usually on the central part of the face. ... more       Show References Hide References

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Immediate Online access to current issue and archives from 1988 to the present
  • Mobile access to our mobile site and free apps for iOS, Android and Kindle
  • FREE online per issue CME/CE
Free trial offer
3 Free Issues of The Medical Letter on Drugs and Therapeutics mailed to your home or office PLUS online access.
Try a Free Trial Subscription
Purchase this article:
Title: Brimonidine Gel (Mirvaso) for Rosacea
Article code: 1427b
 Electronic, downloadable article - $25